Therapeutic potential for HDAC inhibitors in the heart
TA McKinsey - Annual review of pharmacology and toxicology, 2012 - annualreviews.org
Annual review of pharmacology and toxicology, 2012•annualreviews.org
Reversible protein acetylation provides a central mechanism for controlling gene expression
and cellular signaling events. Two pharmacological inhibitors of protein deacetylation are
currently approved for the treatment of human cancer, and numerous follow-on compounds
are in clinical development for oncology and non-oncology indications. The inhibitors target
members of a family of enzymes known as histone deacetylases (HDACs). Surprisingly,
HDAC inhibitors have also been shown to be efficacious in preclinical models of heart …
and cellular signaling events. Two pharmacological inhibitors of protein deacetylation are
currently approved for the treatment of human cancer, and numerous follow-on compounds
are in clinical development for oncology and non-oncology indications. The inhibitors target
members of a family of enzymes known as histone deacetylases (HDACs). Surprisingly,
HDAC inhibitors have also been shown to be efficacious in preclinical models of heart …
Reversible protein acetylation provides a central mechanism for controlling gene expression and cellular signaling events. Two pharmacological inhibitors of protein deacetylation are currently approved for the treatment of human cancer, and numerous follow-on compounds are in clinical development for oncology and non-oncology indications. The inhibitors target members of a family of enzymes known as histone deacetylases (HDACs). Surprisingly, HDAC inhibitors have also been shown to be efficacious in preclinical models of heart failure. This review highlights roles of HDACs in the heart and the therapeutic potential of HDAC inhibitors for the treatment of heart failure.
Annual Reviews